DeSci Meet-up @ JPM
What if we could crowdfund all biomedical research? How can we enable research funding for neglected diseases? How can we fill in the gaps left by federal grants with crypto and blockchains? These are some of the central questions for the growing field of decentralized science and intellectual property non-fungible tokens, being developed at Molecule.
Let’s explore answers to these questions together in this open event. Join us at the Fifty Years HQ in San Francisco for an evening of food and conversation with a community of scientists, blockchain devs, and biotech VCs.
------------------------------------------------------------------
Fifty Years is a pre-seed/seed stage VC firm that partners with founders solving the world's biggest problems through technology entrepreneurship. We've seeded many synthetic biology startups shaping the world for the better -- companies like Solugen (enzymes to make carbon negative chemicals), Upside Foods (real meat without the animals), Ansa Bio (enzymatic DNA synthesis), and Opentrons (wetlab automation).
------------------------------------------------------------------
Molecule is building the core infrastructure to standardize the process of creating and transacting around the early-stage scientific IP. They have also built a launchpad called bio.xyz, to support research-focused decentralized autonomous organizations, such as ValleyDAO and AthenaDAO.
------------------------------------------------------------------
Atria Ventures is a venture capital firm that partners with outlier founders working at edges of biology and human health reimagining the trillion dollar life sciences industry from molecule to patient. We exclusively invest at inception & seed stage.
------------------------------------------------------------------
Pfizer Ventures invests in areas of current or future strategic interest to Pfizer with the goal of remaining at the forefront of life science advances. We identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.